NASDAQ: SLNO - Soleno Therapeutics, Inc.

Yield per half year: +12.81%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Soleno Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2014-11-13
ISIN US8342033094
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://soleno.life
Цена ао 54.92
Change price per day: -4.77% (47.065)
Change price per week: -0.7968% (45.18)
Change price per month: -19.73% (55.84)
Change price per 3 month: -8.77% (49.13)
Change price per half year: +12.81% (39.73)
Change price per year: +11.35% (40.25)
Change price per 3 year: +8 246.37% (0.537)
Change price per 5 year: +2 810.39% (1.54)
Change price per 10 year: 0% (44.82)
Change price per year to date: -20.38% (56.29)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 3.97 4
P/E 0 0
EV/EBITDA -12.41 0
Total: 2.25

Efficiency

Title Value Grade
ROA, % -21.58 0
ROE, % -24.75 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.011 10
Total: 8.2

Growth impulse

Title Value Grade
Yield Revenue, % -51866.73 0
Yield Ebitda, % 132.89 10
Yield EPS, % -85.02 0
Total: 3.6
More

Institutions Volume Share, %
Vivo Capital, LLC 8418093 25.93
Nantahala Capital Management, LLC 5712702 17.6
Perceptive Advisors LLC 3074542 9.47
Carlyle Group Inc. 2857804 8.8
Janus Henderson Group PLC 2523897 7.78
Adage Capital Partners GP L.L.C. 1826814 5.63
Vestal Point Capital, LP 1300000 4
Vanguard Group Inc 969622 2.99
Balyasny Asset Management LLC 926876 2.86
Avoro Capital Advisors LLC 785000 2.42

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Russell 2000 Growth ETF 0.08818 38.04 0.6026
iShares ESG Aware MSCI USA Small-Cap ETF 0.04862 18.09 1.49366
iShares Morningstar Small-Cap Growth ETF 0.04077 587.89 0.72598
iShares Morningstar Small-Cap Growth ETF 0.04077 33.63 0.72598
iShares Morningstar Small-Cap ETF 0.02055 391.25 1.60498
iShares Morningstar Small-Cap ETF 0.02055 30.1 1.60498
iShares Russell 3000 ETF 0.00204 24.83 1.43482



Head Job title Payment Year of birth
Dr. Anish Bhatnagar M.D. President, CEO, COO & Director 1.06M 1970 (55 years)
Mr. James H. MacKaness Chief Financial Officer 640k 1964 (61 year)
Dr. Neil M. Cowen M.B.A., Ph.D. Senior Vice President of Drug Development N/A
Ms. Kristen Yen M.S. Senior Vice President of Clinical Operations 317.19k 1969 (56 years)
Ms. Meredith Manning M.B.A. Chief Commercial Officer N/A 1972 (53 years)
Ms. Patricia C. Hirano M.P.H. Senior Vice President of Regulatory Affairs 493k 1966 (59 years)
Ms. Lauren Budesheim Vice President of People N/A
Dr. Michael Huang M.D. Senior Vice President of Clinical Development N/A 1974 (51 year)
Dr. Raymond W. Urbanski M.D., Ph.D. Chief Development Officer 1959 (66 years)

Address: United States, Redwood City. CA, 203 Redwood Shores Parkway - open in Google maps, open in Yandex maps
Website: https://soleno.life